Patient P-03289

Synthetic patientONX-7 · Day 98 · 35–44 · M · baseline S03Open companion preview

Therapy response

Improving

Tolerance

Deteriorating

GI state

Deteriorating

Inflammatory state

Deteriorating

Nutritional resilience

Declining

Discontinuation risk

56%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 ONX-7 started — Baseline state S03
Day 56 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 59 SC-12 recommended — Supportive Compound SC-12
Day 60 Patient accepted — Started SC-12 in the companion
Day 66 GI-04 recommended — GI Support Protocol GI-04
Day 66 GI symptom burden −24% vs expected — Supportive Compound SC-12
Day 67 Patient accepted — Started GI-04 in the companion
Day 72 Tolerance state changed — Unstable → Improving
Day 75 GI symptom burden −23% vs expected — GI Support Protocol GI-04
Day 80 ME-01 recommended — Monitoring Escalation ME-01
Day 81 Tolerance state changed — Unstable → Improving
Day 81 Patient accepted — Started ME-01 in the companion
Day 84 Deterioration detected before clinical escalation — Monitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 56.

Primary contributors, last 14 days

Treatment adherence-24
Nutritional resilience-7
GI instability+6
Inflammatory activity+5
Toxicity+5

What helped?

Supportive Compound SC-12Day 59
Result: symptom burden −24%
GI Support Protocol GI-04Day 66
Result: symptom burden −23%
Monitoring Escalation ME-01Day 80
Result: deterioration detected before clinical escalation

LIFE OS recommendation

Dosing / Timing Recommendation DT-01

59%

probability of meaningful tolerance improvement

284 similar trajectories
75% showed improvement
median effect visible after 5 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Inflammatory signalling ↑70
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 47
Butyrate / short-chain fatty acid production ↓45
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Drug metabolism and exposure ↑40
- DNACYP2D6 poor metabolizer → higher exposure
Mucosal barrier integrity ↓20
- Daily logGI symptom score 50 and rising
Autonomic recovery ↓20
- WearableShort sleep window

DNA

Fictional pharmacogenomic panel

IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Poor metabolizer
Higher exposure at standard dose

Microbiome

Shannon diversity 1.9 · butyrate capacity 45/100

Akkermansia muciniphilaNormal
Faecalibacterium prausnitziiLow
Bacteroides fragilisHigh
Bifidobacterium longumNormal
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 46 ms
Sleep: 6.0 h
Steps: 4,351
Resting HR: 68 bpm

Daily log: GI score 50, nutritional resilience 46, adherence 56.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
Keep the current walking rhythm
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-03279	46%	S14	GI-04	improved	57
P-03123	40%	S14	GI-04	improved	50
P-03103	37%	S14	GI-04	improved	63
P-03110	37%	S15	GI-04	improved	52
P-03046	36%	S20	GI-04	no change	53
P-03365	36%	S14	NP-02	improved	46
P-03146	35%	S14	GI-04	improved	53
P-03070	34%	S14	GI-04	improved	51
P-03090	34%	S02	GI-04	improved	48
P-03251	34%	S14	SC-12	improved	54
P-03357	34%	S02	CR-01	improved	50
P-03300	33%	S14	GI-04	improved	46